LONDON, April 10, 2014 /PRNewswire/ --
On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 673.27, up 2.11%, and the same has advanced 2.86% in the last three months. Investor-Edge has initiated coverage on the following equities: Seattle Genetics Inc. (NASDAQ: SGEN), Theravance Inc. (NASDAQ: THRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX) and MiMedx Group Inc. (NASDAQ: MDXG). Free technical research on SGEN, THRX, NBIX and MDXG can be downloaded upon signing up at:
Seattle Genetics Inc.'s stock gained 2.87% on Wednesday, closing at $42.27, after oscillating between $41.14 and $42.62. A total of 1.33 million shares were traded, which is above its three months average volume of 1.15 million shares. Seattle Genetics Inc.'s shares have declined 18.37% in the last one month, while the same has advanced 2.22% in the previous three months and 5.97% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages. Seattle Genetics Inc.'s 50-day moving average of $48.61 is above its 200-day moving average of $43.01. Furthermore, the company's stock has a Relative Strength Index (RSI) of 32.76. Sign up today to read free research on SGEN at:
Shares in Theravance Inc. witnessed a trading volume of 1.08 million shares on Wednesday, as compared with its three months average volume of 0.96 million shares. The stock ended the day at $29.62, up 2.28%, after trading between $28.98 and $29.85. Shares in Theravance Inc. have gained 4.41% in the past three trading sessions, while the same has fallen by 15.03% in the last one month and 16.91% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. Theravance Inc.'s 200-day moving average of $36.88 is above its 50-day moving average of $35.12. Additionally, the company's shares have an RSI of 29.39. Sign up today to read free research on THRX at:
On Wednesday, shares in Neurocrine Biosciences Inc. advanced 3.34% finishing the session at $14.53. The stock recorded a trading volume of 0.73 million shares which is below its three months average volume of $1.17 million shares. The stock fluctuated between $14.01 and $14.61 during the session. Shares in Neurocrine Biosciences Inc. have declined 16.97% in the last one month and 20.56% in the previous three months, while the same has advanced 55.57% on YTD basis. The stock is trading above its 200-day moving average. Neurocrine Biosciences Inc.'s 50-day moving average of $16.79 is above its 200-day moving average of $13.50. Moreover, the company's shares have RSI of 33.29. Sign up today to read free research on NBIX at:
MiMedx Group Inc.'s stock recorded a trading volume of 0.38 million shares, as compared with its three months average volume of 0.65 million shares. The stock ended Wednesday's session at $5.96, up 3.83%, and at an intraday trading range of $5.61 and $6.00. MiMedx Group Inc.'s shares have lost 17.68% in the last one month and 31.81% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. MiMedx Group Inc.'s 50-day moving average of $6.91 is above its 200-day moving average of $6.32. Further, the company's shares have an RSI of 33.68. Sign up today to read free research on MDXG at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.